by 
Autologous stem cell therapy utilizes stem cells derived from the patient’s own body to repair or regenerate damaged tissues or cells. It is an emerging regenerative medicine approach for treating various degenerative diseases such as neurological disorders, orthopedic disorders, and cardiovascular conditions. The therapy avoids complications associated with immunosuppression and graft rejection.
The global Autologous Stem Cell and Non-Stem Cell Based Therapies Market is estimated to be valued at US$ 98.8 Bn in 2024 and is expected to exhibit a CAGR of 0.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increasing investment in R&D is one of the major trends fueling the growth of the autologous stem cell and non-stem cell based therapies market. Companies operating in the market are focusing on clinical trials and experimental studies to validate therapeutic applications of stem cells. For instance, Caladrius Biosciences received an investment of USD 7.5 million from the California Institute for Regenerative Medicine for preclinical and clinical development of autologous CD34+ cell therapy for cardiovascular indications. Similarly, Vericel Corporation received an orphan drug designation from the U.S FDA for its stem cell therapy MACI for the treatment of pediatric patients with symptomatic articular cartilage lesions of the knee. Such initiatives will help enhance the pipeline of stem cell-based therapies and boost the market growth over the forecast period.
SWOT Analysis
Strength: Autologous stem cell therapies utilize patient’s own cells to treat diseases, avoiding risks of rejection. Non-stem cell therapies rely on existing approvals and proven safety/efficacy to address unmet medical needs.
Weakness: Significant R&D investments and clinical trials required to develop new autologous cell therapies. Supply chain complexities in collecting, processing, and administering customized treatments.
Opportunity: Aging population driving demand for treatments addressing degenerative conditions. Emerging cell therapy applications across neurology, cardiology, and orthopedics indication segments.
Threats: Stringent regulatory approvals and infrastructure requirements increase barriers. Reimbursement uncertainties pose commercialization challenges. Emergence of alternative treatment options.
Key Takeaways
The global Autologous Stem Cell and Non-Stem Cell Based Therapies market is expected to witness high growth over the forecast period of 2023 to 2030. The global Autologous Stem Cell and Non-Stem Cell Based Therapies Market is estimated to be valued at US$ 98.8 Bn in 2024 and is expected to exhibit a CAGR of 0.0% over the forecast period 2023 to 2030.
North America currently dominates the market and is expected to continue its dominance over the forecast period. This is attributed to the favorable regulatory environment, rise in investment in R&D for cell therapies, and presence of major market players. Asia Pacific is expected to grow at the fastest rate supported by rising healthcare expenditure, increasing incidence of diseases, and growing expertise in stem cell research.
Key players operating in the Autologous Stem Cell and Non-Stem Cell Based Therapies market are Caladrius Biosciences, Vericel Corporation, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation. Caladrius Biosciences focuses on developing clinical-stage autologous cell therapies for cardiovascular and orthopedic indications. Vericel Corporation markets cell therapies for difficult-to-treat wound, burn, and skin repair applications.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
